

CURRICULUM VITAE DI TRAVELLI CRISTINA

PERSONAL INFORMATION

Name: Cristina Travelli
Citizenship: Italian
Date/Place of birth: 19/11/1985, Borgomanero (NO)
Address: via Valsesia, 37e, 28047 Oleggio (NO)
E-mail: cristina.travelli@unipv.it
Mobile: 0039 3490516578
Spoken Languages: English (C2), French (B2), German (A1)

WORKING INFORMATION

University: University of Pavia
Department: Department of Pharmaceutical Sciences
Address: viale Taramelli 12, 27100, Pavia, ITALY
Telephone/fax: 0039 0382 987402
Scopus ID: 23989511500

ACADEMIC CAREER

2018: National habilitation in Pharmacology

2009-2013: Ph.D. in Food and Drug Biotechnologies at “Università del Piemonte Orientale” (UPO)

2007-2009: Master’s Degree in Medical and Pharmaceutical Biotechnologies at “Università del Piemonte Orientale” (UPO)

2004-2007: Bachelor’s Degree in Biotechnologies at “Università del Piemonte Orientale” (UPO)

PROFESSIONAL EXPERIENCE

2022-present: Associate professor In Pharmacology, at University of Pavia, Italy.

2019-2021: Tenure Track Professor (Ricercatore a tempo determinato-tipologia B; RTD-B) at University of Pavia, Italy.

Research area: study of novel therapeutic agents in inflammatory disorders and breast cancer.

2018-2019: Contract Professor of Pharmacology at Università del Piemonte Orientale in the Biotechnology bachelor degree.

2018: Umberto Veronesi Fellow at Department of Pharmaceutical Sciences DSF, Novara, Italy.

Research area: Targeting eNAMPT in triple negative breast cancer

2017-2018: Teaching assistant (Cultore della Materia) in Pharmacology, (UPO), Novara, Italy.

2016-present: collaboration with Dr. Rita De Sanctis, Cancer Center, Istituto Clinico Humanitas
Protocol approved: Immuno-metabolomic profiling of Soft Tissue Sarcomas and Breast Cancer

2016-2018: Post-Doc position in the Lab of Prof. Armando Genazzani, Department of Pharmaceutical Sciences DSF, Novara, Italy.

Research area: Targeting eNAMPT in inflammatory-bowel disease (IBD)

2015-present: collaboration with Prof. Mario Paolo Colombo, Istituto Nazionale Tumori, Milano, Italy.

Research area: role of NAMPT in myelopoiesis

2014- present: collaboration with Prof. Fabio Malavasi in Laboratory of Immunogenetics, University of Torino, Italy.

Research area: Generation and characterization of eNAMPT monoclonal antibodies

2013-2016: FIRC fellowship at Department of Pharmaceutical Sciences DSF, Novara, Italy.

Research area: Intra- and Extra-cellular NAMPT in myeloid-derived suppressor cells

2011-2012: experience in the Lab of Prof. Antonio Sica, Istituto Clinico Humanitas (ICH), Rozzano, Italy.

Research area: characterization of the role of NAMPT and NAD metabolism in immune cells in cancer

2009-2013: experience in the Lab of Prof. Armando Genazzani, DSF, Novara, Italy.

Research area: Targeting Nicotinamide Phosphoribosyltransferase (NAMPT) in cancer Therapy

2006-2009: experience in the Lab of Prof. Armando Genazzani, DSF, Novara, Italy.

Research area: NAD metabolism and characterization of NAMPT inhibitors as autophagy Inducers

Career Breaks: none

HONOURS and AWARDS

2020: Winner of the Grant "Ricerca biomedica condotta da giovani ricercatori 2020" (249.300€).

2019: Grant 2019 FONDAZIONE UMBERTO VERONESI: 1 -year Post-Doctoral fellowship in Oncology (27000€), declined

2018: Grant 2018 FONDAZIONE UMBERTO VERONESI: 1 -year Post-Doctoral fellowship in Oncology (27000€)

2017: Travel Grant: "Brainstorming Meeting on CD38 and CD157", San Benedetto PO- Mantova

2017: Gianfranco Ferro Fellowship-SIF, Title: "TARGETING EXTRACELLULAR NICOTAMIDE PHOSPHORIBOSYL TRANSFERASE (eNAMPT) IN BREAST CANCER" (10000 €), declined

2015: AACR-Travel Grant: American Association for Cancer Research (AACR)-Pezcoller Foundation Scholar-In-Training Award Travel, Philadelphia, (1500\$)

2013-2016: 3 years AIRC-FIRC fellowship "Leonino Fontana e Maria Lionello"(70000€)

2013: Prize SIF-TAKEDA from "Società Italiana di Farmacologia (SIF)" and Takeda for the best project in Onco-Pharmacology (12500 €)

2013: Prize SIF per best oral communication, Antineoplastic Drugs at 36[^] Congresso nazionale della Società Italiana di Farmacologia (SIF) 2013 (500€)

LEARNED SOCIETIES AND BOARDS

Learned Societies and Boards

SIF - Società Italiana di Farmacologia

ECCO- European Crohn's and Colitis Organisation

AACR- American Association for Cancer Research

EDITORIAL ACTIVITIES

2020-now: Biology guest editor, MDPI, "Inflammation in cancer: a target for prevention and therapy"

2020-present: Reviewer Board of Frontiers in Immunology

FUNDING

2022: Co-Pi in GR-2021- 123738842021 (65000 €)

2020-present: Bando Cariplo Giovani ricercatori: PI of the project "Extracellular Nicotinamide Phosphoribosyltransferase (eNAMPT): role in the pathogenesis and progression of Inflammatory Bowel Diseases".

2017-2019: PI in the study of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors funded by ANGELINI S.p.A. Contract title: "Studi di farmacocinetica, efficacia e di safety dei lead MV87, MS33 a MD65".

AIRC- 2018: co-applicant with Prof. Genazzani. Title project: "Extracellular NAMPT in breast cancer: roles and evaluation of the therapeutic potential of its neutralization", AIRC.

PRIN-2015: co-applicant with Prof. Genazzani. Title Project "Attività antinfiammatoria dei Glucocorticoidi: nuovi mediatori e regolazione dell'attività dei linfociti T". PI: Carlo Riccardi

AIRC-2013: co-applicant with Prof. Genazzani. Title project: "The NAD salvage Pathway as a therapeutic target in melanoma", AIRC IG10509

Compagnia San Paolo- 2012: co-applicant with Prof. Genazzani at oncoNAMPT-Compagnia San Paolo (CUP: C61J12000280007) project: "Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Potential Chemotherapeutic Agents (oncoNAMPT)".

PATENT, SPIN OFF E START UP

PATENT-2014: International patent PCT/IB2014/061080- WO2014178001, "Inhibitors of Nicotinamide Phosphoribosyltransferase, compositions, products and use thereof".

36 publications

Citations: **1090**

H-index: **20**

Source: Scopus

Selected poster/oral presentations at international congress

Cristina Travelli has participated and presented oral communications at several national and international congresses.

- FASEB, Federation of American Societies for Experimental Biology Conferences (NAD metabolism), Hamburg Germany (2008), Lucca Italy (2011).

- Società Italiana di Farmacologia (SIF) (every year from 2008, with several oral communications), Italian Society of Immunology, Clinical Immunology and Allergology (SIICA, 2014)

- American Association for Cancer Research (AACR) Congress (Chicago 2012, Philadelphia 2013).

- European Crohn's and Colitis Organisation (ECCO) congress (Vienna 2018)

FASEB- Federation of American Societies for Experimental Biology Conferences "NAD metabolism and signalling", Lucca (IT).

Title: "Nicotinamide Phosphoribosyl Transferase (NAMPT) Inhibitors as Anti-Cancer Agents in Neuroblastoma"(04-09-2011; 09-09-2011)

AACR, American Association for Cancer Research, Annual Meeting 2012, Chicago, (USA).

Title: "Nicotinamide Phosphoribosyl Transferase (NAMPT) is over-expressed in Melanoma" (30-03-2012; 04-04-2012)

AACR, American Association for Cancer Research, Annual meeting 2015, Pennsylvania Convention Center Philadelphia, Pennsylvania, (USA).

Title: "Nicotinamide phosphoribosyl transferase (NAMPT) inhibitors: novel modulators of antitumor immunity" (18-04-2015; 22-04-2015)

51st Congress of European Society for clinical Investigation (ESCI), Phagocyte Biology workshop, Genova (IT).

Title: "NAMPT integrates metabolism and immunosuppressive activity of tumour associated myeloid cells" (17-05-2017; 19-05-2017)

Brainstorming meeting on CD38 and CD157, San Benedetto Po-Mantova.

Title: "Extracellular Nicotinamide Phosphoryltransferase (NAMPT) as a novel therapeutic target in inflammation and cancer" (21-09-2017; 23-09-2017)

13th Congress of European Chron's and Colitis Organization (ECCO) 2018, Vienna, Austria.

Title: "Extracellular Nicotinamide Phosphoribosyltransferase (eNAMPT): A possible new target in inflammatory bowel diseases" (14-02-2018; 17-02-2018)

Cristina Travelli is a Researcher at University of Pavia. During her training and postdoctoral experiences, she has gathered considerable experience in molecular biology, cellular biology, cell culture, primary cell culture isolation such as experience in the isolation of immune cells (from blood, spleen, lymph nodes, bone marrow and lamina propria) and flow cytometry analysis. During her career, she has also participated in drug discovery academic enterprises on small molecules and she is the scientific responsible of two approved protocols from the Ministry of Health for in vivo experiments (authorization DB064.30, n°245/2018; DB064.27, n°120/2018).

Now, her primary research interest is to investigate novel pharmacological targets in the field in cancer and in inflammatory disorders. Dr. Travelli has expertise in immunology and in immunotherapy and she is currently ongoing several preclinical evaluations, with the aim to discover novel immune-modulating agents as therapeutic strategies in cancer inflammatory disorders.

19-01-2023

